Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long‐term goal of developing immunological criteria for managing IM therapy in CML patients, we compared the immunophenoty...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Mizuguchi, Junichiro, Tauchi, Tetsuzo, Kimura, Yukihiko, Inokuchi, Koiti, Ohyashiki, Junko H., Ohyashiki, Kazuma
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656535/
https://ncbi.nlm.nih.gov/pubmed/23758044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12216
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires